These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37402640)

  • 1. Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis.
    Han SH; Safeek R; Ockerman K; Trieu N; Mars P; Klenke A; Furnas H; Sorice-Virk S
    Aesthet Surg J; 2023 Dec; 44(1):60-67. PubMed ID: 37402640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
    Humphrey CD; Lawrence AC
    Facial Plast Surg; 2023 Dec; 39(6):719-721. PubMed ID: 37541662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.
    Watanabe JH; Kwon J; Nan B; Reikes A
    J Am Pharm Assoc (2003); 2024; 64(1):133-138. PubMed ID: 37821008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon.
    Carboni A; Woessner S; Martini O; Marroquin NA; Waller J
    J Drugs Dermatol; 2024 Jan; 23(1):1367-1368. PubMed ID: 38206146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-Like Peptide-1 Receptor Agonist Users.
    Toms JA; O'Neill E; Wiegmann AL; Adepoju J; Raj MS
    Aesthet Surg J; 2024 Apr; ():. PubMed ID: 38620005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semaglutide (Ozempic
    Mailhac A; Pedersen L; Pottegård A; Søndergaard J; Mogensen T; Sørensen HT; Thomsen RW
    Clin Epidemiol; 2024; 16():307-318. PubMed ID: 38685990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In brief: GI effects of GLP-1 receptor agonists.
    Med Lett Drugs Ther; 2023 Nov; 65(1690):191-192. PubMed ID: 37983121
    [No Abstract]   [Full Text] [Related]  

  • 8. Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future.
    O'Neill ES; Wiegmann AL; Parrella N; Pittman T; Hood K; Kurlander D
    Plast Reconstr Surg Glob Open; 2024 Jan; 12(1):e5516. PubMed ID: 38268718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 agonists: A review for emergency clinicians.
    Long B; Pelletier J; Koyfman A; Bridwell RE
    Am J Emerg Med; 2024 Apr; 78():89-94. PubMed ID: 38241775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss.
    Han SH; Ockerman K; Furnas H; Mars P; Klenke A; Ching J; Momeni A; Sorice-Virk S
    Aesthet Surg J; 2024 Mar; 44(4):NP279-NP306. PubMed ID: 38085071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a pharmacist-led weight management service in a cardiology clinic.
    Yates M; Supple M; Maccia M
    J Am Pharm Assoc (2003); 2024; 64(2):557-563. PubMed ID: 37944862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
    Singh G; Krauthamer M; Bjalme-Evans M
    J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders.
    Bremmer MP; Hendershot CS
    J Stud Alcohol Drugs; 2024 Jan; 85(1):5-11. PubMed ID: 37917019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaglutide: First Global Approval.
    Dhillon S
    Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus.
    Billings LK; Handelsman Y; Heile M; Schneider D; Wyne K
    J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S30-S41. PubMed ID: 30156447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.
    Handelsman Y; Wyne K; Cannon A; Shannon M; Schneider D
    J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S14-S29. PubMed ID: 30156445
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.